Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Other hematologic neoplasm 3Lymphoid 3Genitourinary 2Gastrointestinal 2Dermatologic 2Head & Neck 1CNS 1

Conditions

Brain Neoplasms 640Glioblastoma 573Glioma 407Neuroblastoma 174Neoplasms 125Astrocytoma 107Central Nervous System Neoplasms 105Medulloblastoma 89Breast Neoplasms 86Meningioma 85Carcinoma, Non-Small-Cell Lung 78Melanoma 76Lung Neoplasms 70Sarcoma 65Ependymoma 64Neurofibromatosis 1 62Recurrence 50Neoplasm Metastasis 48Oligodendroglioma 47Meningeal Carcinomatosis 47Osteosarcoma 46Diffuse Intrinsic Pontine Glioma 45Rhabdomyosarcoma 44Pheochromocytoma 44Paraganglioma 42Rhabdoid Tumor 41Gliosarcoma 40Pancreatic Neoplasms 39Sarcoma, Ewing 38Colorectal Neoplasms 33

Interventions

Temozolomide 1Irinotecan 1Cefixime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × CNS × 1 year × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡